Gene editing strategy may control insect-borne diseases

However, the innovative nature of gene drives poses regulatory challenges.

“Simply put, gene drives do not fit comfortably within existing US regulations and international conventions,” said Kenneth Oye, PhD, of the Massachusetts Institute of Technology in Cambridge.

“For example, animal applications of gene drives would be regulated by the FDA as veterinary medicines. Potential implications of gene drives fall beyond the purview of the lists of bacteriological and viral agents that now define security regimes. We’ll need both regulatory reform and public engagement before we can consider beneficial uses. That is why we are excited about getting the conversation on gene drives going early.”